Komplementärmedizinisches Nebenwirkungsmanagement, Teil 2

Einleitung

Im vorliegenden Teil 2 wird eine kurze Zusammenfassung geeigneter und möglichst evidenzbasierter, komplementärmedizinischer Behandlungsmethoden vorgestellt, die sich für die Behandlung relevanter Leitsymptome besonders eignen. Unterschiedliche, häufig die Lebensqualität einschränkende Leit-(Leid-)symptome können im Verlauf einer Tumorerkrankung als Folge der Therapie oder der Erkrankung auftreten.

Literatur

• 01 Berger M. Effect of alpha-lipoic acid on the chemotherapeutic efficacy of cyclophosphamide and vincristinsulfate.  Arzneimittelforschung. 1983;  33 (9) 1286-8
• 02 Busam K J. Cutaneous side effects in cancer patients treated with the anti-EGFR antibody C22 %.  Br J Dermatol. 2001;  144 (6) 1169-76
• 03 Cavaletti G. Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor.  Neurosci Lett. 2002;  322 103-106
• 04 Cersosimo R J. Oxaliplatin-associated neuropathy: a review.  Ann Pharmacother. 2005;  39 128-35
• 05 Christ H W. Immunmodulierende Therapie bei Psoariasis vulgaris durch Fumarsäure, Thymuspeptide und Selen.  Erfahrungsheilkunde. 2003;  52 (9) 573-77
• 06 Coudray. Selenium supplementation decreases the the pro-oxidant and cardiotoxicity effects of adriamycin in the rat.  Redox Rep. 1996;  2 (5) 323-32
• 07 Daniele B. et al . Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial.  Gut. 2001;  48 28-33
• 08 Duncan M. Oral and intestinal mucositis-causes and possible treatments.  Aliment Pharmacol Ther. 2003 ;  18 (9) 853-74
• 09 Elbl L. The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer.  Eur J Pediatr. 2003;  162 (10) 690-6
• 10 Friedrichsen H P. Darmschleimhaut-Barriere, intestinale Immunregulation und Mikronährstoffe.  OM - Zs f Orthomol Med. 2004;  2 (3) 4-9
• 11 Gedlicka C. Ameloriation of docetaxel/cisplatin induced polyneuropathy with alpha-lipoic acid.  Ann Oncol. 2003;  14 (2) 339-40
• 12 Gedlicka C. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid.  J Clin Oncol. 2002;  20 (15) 3359-61
• 13 Hartwich R. Klinikarzt. 1998;  6 27
• 14 Hequet O. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.  J Clin Oncol. 2004;  22 (10) 1864-71
• 15 Hiddemann W, Huber H, Bartram C R. Die Onkologie. Teil 1 Berlin/Heidelberg; Springer 2004: 419-20
• 16 Hong Y M. Effect of L-carnitine on carnitine palmitoyltransferase activities and plasma carnitine concentrations in adriamycin-treated rats.  Pediatric Research. 2003;  53 788-92 published online before print March 5, 2003 
• 17 Hu Y J. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients.  Biol Trace Elem Res. 1997;  (3) 331-41
• 18 Hung L M. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes.  Cardiovasc Res. 2000;  47 (3) 549-55
• 19 Iarussi D. Protective effect of coenzyme Q 10 on anthracyclines cardiotoxicity: control-study in children with acute lymphoblastic leukaemia and non-Hodgkin lymphoma.  Mol Aspects Med. 1994;  15 (S 207-12)
• 20 Laumann M K. et al .Effect of Pyridoxine on the Incidence of Palmar Plantar Erythroderma (PPE) in Patients receiving Capecitabin. Abstracts ASCO 2001
• 21 Lee M W. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa, an inhibitor of epidermal growth factor.  Acta Derm Venereol. 2004;  84 (1) 23-6
• 22 Naziroglu M. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissue in rats.  Toxicology. 2004;  (2-3) 221-30
• 23 Pisano C. Paclitaxel and cisplatin-induced neurotoxicity.  Clin Cancer Res. 2003;  9 (15) 5756-67
• 24 Risum S. Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment.  Ugeskr Laeger. 2003;  165 (33) 3161-2
• 25 Sayed-Ahmed M. Propionyl-L-carnitine as protector against adriamycin-induced cardiomyopathy.  Pharmacol Res. 2001;  43 (6) 513-20
• 26 Sayed-Ahmed M M. Propionyl-L-carnitine as potential protective agent against adriamycin-induced impairment of fatty acid beta-oxidation in isolated heart mitochondria.  Pharmacol Res. 2000;  41 (2) 143-50
• 27 Strauss M. Carnitine promotes heat shock protein synthesis in adriamycin-induced cardiomyopathy in a neonatal rat experimental model.  J Mol Cell Cardiol. 1998;  30 2319-25
• 28 Unger C. Arzn. Forsch./Drug Res.  2001;  51 1
• 29 Vukelja S J. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere.  J Natl Cancer Inst. 1993;  85 (17) 1432-3
• 30 Walon L. Acneiform eruptions induced by cetuximab.  Ann Dermatol Venerol. 2003 ;  130 (4) 443-6
• 31 Ziegler T. et al . Glutamine supplementation in cancer patients receiving bone marrow transplantation and high dose chemotherapy.  Journal of Nutrition. 2001;  131 2578S-84S

Korrespondenzadresse